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Abstract In cardiac muscle, the sarcolemmal sodium/
potassium ATPase is the principal quantitative means of
active transport at the myocyte cell surface, and its activity
is essential for maintaining the trans-sarcolemmal sodium
gradient that drives ion exchange and transport processes
that are critical for cardiac function. The 72-residue phos-
phoprotein phospholemman regulates the sodium pump in
the heart: unphosphorylated phospholemman inhibits the
pump, and phospholemman phosphorylation increases
pump activity. Phospholemman is subject to a remarkable
plethora of post-translational modifications for such a small
protein: the combination of three phosphorylation sites, two
palmitoylation sites, and one glutathionylation site means
that phospholemman integrates multiple signaling events to
control the cardiac sodium pump. Since misregulation of
cytosolic sodium contributes to contractile and metabolic
dysfunction during cardiac failure, a complete understand-
ing of the mechanisms that control the cardiac sodium pump
is vital. This review explores our current understanding of
these mechanisms.
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Abbreviations
CFP Cyan fluorescent protein
E–C Excitation–contraction
FRET Fluorescence resonance energy transfer
PLB Phospholamban
PLM Phospholemman
PKA Protein kinase A
PKC Protein kinase C
NCX Sodium-calcium exchanger
NO Nitric oxide
SR Sarcoplasmic reticulum
YFP Yellow fluorescent protein
Introduction
In 1997, a share of the Nobel Prize in Chemistry was
awarded to Jens Christian Skou for his 1957 discovery of
the Na, K ATPase [1]. This ubiquitous P-type ATPase links
the hydrolysis of ATP to the cellular export of three sodium
ions and import of two potassium ions against their elec-
trochemical gradients. Subsequent work by Skou and
countless other research groups worldwide established the
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Na/K ATPase (Na pump) as an indispensable means of
active membrane transport in essentially every eukaryotic
single and multi-cellular organism, and the molecular tar-
get of the foxglove extracts digitalis and digoxin, in clinical
use for heart failure since the 18th century.
While the use of Na pump-inhibiting cardiotonic ste-
roids for the management of heart failure is now restricted
to only a small subset of patients [2], our understanding of
the biology and regulation of the Na pump has blossomed.
In the past 5 years, the discovery [3] and refinement [4–7]
of crystal structures in potassium and ouabain-bound states
has further advanced our understanding of the structure–
function relationship of this much-studied macromolecular
complex. The Na pump is subject to multiple regulatory
mechanisms in essentially every tissue in which it is
expressed that are beyond the scope of this review, which
will focus solely on the regulation of the cardiac enzyme.
Quaternary structure
The Na pump is a multi-subunit enzyme with a minimum
requirement for an a and b subunit to form a functional
pump. The *100-kDa a subunit is the catalytic core of the
enzyme, containing the binding sites for sodium, potas-
sium, and ATP as well as cardiotonic steroids such as
ouabain. It requires an obligatory association with a b
subunit to traffic through the secretory pathway to the
plasma membrane [8, 9]. The discovery of a third subunit,
the c subunit in the kidney [10], eventually led to the
realization that a third protein may more generally form
part of the pump complex [11]. Whether this third member
of the complex, named a FXYD protein for the conserved
extracellular phenylalanine-X-tyrosine-aspartate motif, is a
constant or occasional companion of the pump has not been
rigorously investigated to date. The existence of four iso-
forms of the a subunit, three isoforms of b, and seven
FXYD proteins (as well as splice variants of the c subunit
[12]) in mammalian genomes can theoretically support the
assembly of over 100 functionally different Na pumps to
fulfill different physiological requirements.
Cardiac subunit composition
Although four isoforms of the a subunit have been iden-
tified, only a1 and a2 are reportedly expressed at significant
levels in cardiac myocytes [13, 14]. That said, we [15] and
others [16] readily detect a3 subunit expression in cardiac
tissue (which may not reflect a myocyte-derived pool), and
the a3 subunit is reported to replace the a2 subunit in
experimental models of heart failure [17]. Both the a1 [18]
and a2 [14] subunits of the Na pump are functionally
linked to the Na/Ca exchanger (NCX) in ventricular
myocytes, however the subcellular distribution of these two
isoforms is different, with the a2 subunit found more
concentrated in t-tubular membranes than the a1 subunit
[19]. This has led to some proposing different physiologi-
cal roles for these two subunits [14, 20], although this
hypothesis has been challenged [21]. Experiments in
transgenic animals in which the ouabain affinities of a1 and
a2 isoforms of the pump are reversed clearly indicate that
both a1 and a2 are functionally and physically coupled to
NCX in the heart [18]. Recent experiments using the same
transgenic model suggest that the functional coupling of
a2-containing pumps to NCX has a greater impact on
myocyte calcium handling than the functional coupling of
a1-containing pumps [22]. When a1- or a2-containing
pumps are selectively blocked to give similar rises in
intracellular sodium, only a2 block increases calcium
transient amplitude. This suggests that a2 pumps control
sodium and therefore calcium in sarcolemma/sarcoplasmic
reticulum microdomains via NCX, and a1 pumps are
responsible for maintaining a separate (possibly global)
pool of sodium [22].
In the mouse, approximately 70 % of functional a2 and
40 % of a1 subunits are t-tubular, even though the t-tubule
membranes represent only 30 % of total surface area [19].
The contribution of the a1 isoform dominates the a2 in all
surface membrane compartments, but it is much less
dominant in the t-tubules [19]. A similar functional con-
centration in t-tubules [23] and isoform distribution is
reported for the rat [24]. Prevailing opinion therefore cur-
rently favors the concept that while both a1 and a2 subunits
of the pump are involved in regulation of excitation–con-
traction (E–C) coupling, a2 containing pumps are
principally concerned with regulation of contractility, and
a1 containing pumps control both contractility and bulk
intracellular sodium. There are undoubted differences in the
manner in which a1 and a2 pumps are regulated hormonally
(see ‘‘Basal phosphorylation of phospholemman’’), and the
biochemical basis of the differential targeting of Na pump
a1 and a2 containing enzymes has not yet been established.
The principle b subunit found in cardiac muscle is b1
(although we also routinely detect the b3 subunit in pro-
teomic screens from ventricular myocytes [15]), and the
principal FXYD protein is phospholemman (PLM).
FXYD5 (RIC) has also been reported to be present in
homogenates from whole hearts [25], but whether this
derives from a myocyte or non-myocyte population
remains to be investigated.
Importance of pump regulation in the heart
In excitable tissues, the activity of the plasmalemmal Na
pump is vital for the maintenance of normal electrical
activity and ion gradients. In cardiac muscle, the transar-
colemmal sodium gradient established by Na pump activity
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is essential not only for generating the rapid upstroke of the
action potential but also for driving a number of ion
exchange and transport processes critical for normal cel-
lular function, ion homeostasis, and the control of cell
volume. These sodium-dependent membrane transporters
include those responsible for the regulation of other ions
(such as NCX, Na/H exchanger, and Na-HCO3 cotrans-
porter [26]), as well as those involved in the movement of
substrates and amino acids (see Table 1) [27]. For exam-
ple, by controlling steady-state intracellular sodium, the
pump determines the set-point for intracellular calcium
(Ca) via NCX, which in turn determines the sarcoplasmic
reticulum (SR) calcium content. Precise control of cyto-
solic and SR calcium concentrations is essential in
maintaining cardiac output: derangement of calcium han-
dling is a primary cellular cause of contraction
abnormalities and heart failure. Interventions that influence
either the set point of the Na pump, or indirectly the
transarcolemmal sodium gradient, can therefore profoundly
affect myocardial function. In essence, the Na pump indi-
rectly controls myocardial contractility [28].
Pump regulation by the prevailing cellular environment
ATP
The Km of the cardiac Na pump for intracellular ATP has
variously been estimated to range from 0.46 mM (embry-
onic chick hearts [30]) to 0.21 mM (dog sarcolemmal
vesicles [31]) to 94 lM (giant patches from guinea-pig,
rabbit, and mouse myocytes [32]). In rat ventricular myo-
cytes, intracellular ATP is generally high enough to be
non-limiting for the Na pump: even following metabolic
inhibition, ATP concentration only declines to a limiting
concentration at about the time of onset of rigor-contrac-
ture [33]. Interestingly, there is evidence that the pump is
functionally coupled to glycolytic rather than oxidatively
generated ATP [34], much as has been reported for other
sarcolemmal ion transporters [35], although the molecular
basis for this remains to be established.
Intracellular sodium
The affinity of the cardiac pump for sodium has been
reported for a number of species and using a variety of
techniques. The Km for sodium has variously been esti-
mated as: 9 mM (dog sarcolemmal vesicles [31]), 14 mM
(sheep Purkinje fibers [36]), 11 mM (guinea-pig ventricular
myocytes [37]), 19 mM (rabbit ventricular myocytes [38]),
19 mM (mouse ventricular myocytes [39]). Inter-species
variations in resting intracellular sodium concentrations in
ventricular myocytes have also been reported [40], but what
is beyond doubt is that intracellular sodium sits close to the
sodium affinity of the pump, such that small changes in
intracellular sodium elicit large changes in pump activity.
That said, the sodium concentration seen by the pump may
actually differ from bulk resting cytosolic sodium.
Sub-sarcolemmal barriers and fuzzy spaces
The idea that sub-sarcolemmal sodium gradients not only
exist but may dynamically change to influence E–C
Table 1 Mammalian cell surface translocators whose activity relies
on the transmembrane Na gradient
Translocator Stoichiometry Charge flux
Ions
Na channel N/A -ve
Na/Ca exchanger 3:1 -1
Na/H exchanger 1:1 Neutral
Na/Mg exchanger 2:1 Neutral
Na/K/Cl co-transporter 1 ? 1 ? 2 Neutral
Na/HCO3 co-transporter 1 ? 2 ?1
Na/I co-transporter 2 ? 1 -1
Substrates
Na/glucose co-transporter 2 ? 1 -2
Na/mannose co-transporter 1 ? 1 -1
Na/Cl/creatine co-transporter 2 ? 1 ? 1 -1
Na/succinate co-transporter 3 ? 1 -1
Amino acids
Na/Cl/taurine co-transporter 3 ? 1 ? 1 -2
Na/glutamate/K exchanger 3 ? 1:1 -1
Na/Cl/glycine co-transporter 3 or 2 ? 1 ? 1 -2 or -1
Na/alanine co-transporter 1 ? 1 -1
Na/Cl/GABA co-transporter 2 ? 1 ? 1 -1
Na/Cl/proline co-transporter 3 ? 1 ? 1 -1
Na/arginine co-transporter 1 ? 1 -2
Na/glutamine/H exchanger 2 ? 1:1 -1
Others
Na/ascorbate co-transporter 2 ? 1 -1
Na/citrate co-transporter 3 ? 1 -1
Na/monocarboxylate co-transporter 2 ? 1 -2
Na/Pi co-transporter 3 ? 1 -1
Na/sulphate co-transporter 3 ? 1 -1
Na/bile acid co-transporter 2 ? 1 -1
Na/nucleoside co-transporters 1 ? 1 Neutral
Na/inositol co-transporter 1 ? 1 -1
Na/Cl/dopamine co-transporter 2 ? 1 ? 1 -2
Na/Cl/noradrenaline co-transporter 1 ? 1 ? 1 -1
Na/Cl/serotonin/K exchanger 2 ? 1 ? 1:1 -1
Na/carnitine co-transporter 1 ? 1 -1
By convention, inward positive charge movement is classified as a
negative flux. Modified from [29]
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coupling was first proposed by Lederer et al. [41] and
Leblanc and Hume [42] in 1990. This raised the possibility
that the Na pump may both respond to, and influence,
limited pools of sodium in a sub-sarcolemmal space. There
is now ample evidence for a diffusional barrier between a
sub-sarcolemmal pool of sodium available to the pump and
the bulk cytosolic pool in cardiac muscle [43–48]. Hence,
while sodium availability is one of the principal determi-
nants of pump activity in all cell types, in cardiac muscle in
particular, the activity of co-localized sodium influx path-
ways which ‘‘charge’’ this sub-sarcolemmal pool may be an
important controller of the pump. Chief among these is
NCX, which has been suggested to be functionally coupled
to the pump [14, 18], and whose expression and activity is
significantly elevated in some experimental models of heart
failure (for example [49, 50]). Hence, while the pump
acutely controls NCX (see above), changes in NCX-driven
sodium transport may also drive long-term changes in flux
through the pump when, for example, downregulation of
SERCA in the failing heart causes myocytes to become
more dependent on NCX to remove calcium during dias-
tole [49, 50].
While the pump may functionally interact with NCX,
the situation may be more complex. As discussed above
(‘‘Cardiac subunit composition’’), a1 and a2-containing
isoforms may be both spatially and functionally separate.
a2 expression is concentrated in the t-tubules, along with
other key components of E–C coupling, while a1 is more
evenly distributed across the sarcolemma and has been
suggested to play a more ‘‘housekeeping’’ role in regulat-
ing bulk cytoplasmic sodium [14, 18–20, 22]. Thus, it may
be inappropriate to think of the cell as two simple com-
partments, bulk cytosol and sub-sarcolemmal space, but
rather as multiple compartments where co-localization of
ion transporters creates microdomains of locally controlled
sodium. However, in this regard, both Weber et al. [51] and
Silverman et al. [48] failed to detect evidence that the
cardiac sodium current elevates sodium in a sub-sarco-
lemmal space sensed by either NCX or NKA at
physiological potentials. While this leaves open the pos-
sibility that NCX and NKA occupy the same sub-
sarcolemmal compartment, it seems that sodium in this
compartment does not change in the milliseconds follow-
ing sodium entry via the fast inward current. While this
may be the case in healthy single cardiac myocytes under
controlled experimental conditions, there is ample evi-
dence that other sodium influx pathways are also
upregulated in the failing myocardium [52, 53], which
leads to elevated steady-state bulk sodium in failing myo-
cytes, and therefore higher steady-state flux through the
pump [52]. Added to this, changes in the expression of
pump catalytic and regulatory subunits contribute to altered
pump function in heart failure [16].
Membrane potential
The activity of the Na pump is strongly influenced by
membrane voltage [24, 37, 38, 54]. Thus, during the action
potential, even if the trans-sarcolemmal ion gradients
remain unchanged, pump activity both responds to, and can
influence, membrane potential. The voltage-dependence of
the pump typically shows some inward rectification at
positive potentials [37, 38, 54]. At rest, pump inhibition
depolarizes the membrane by only a few millivolts as the
relatively small pump current is dominated by the large
potassium conductance of the resting membrane (IK1).
However, during the plateau of the action potential, the
input impedance of the membrane is significantly raised
(due to the inward rectification of IK1) and hence the pump
current, which is itself increased by depolarization, may
have a more significant impact on membrane potential with
pump stimulation shortening, and inhibition prolonging,
the duration of the action potential [55].
The influence of voltage on pump current differs
between the two main cardiac isoforms [24, 56]. While
both subunits are activated by voltage, and show inwardly
rectifying current–voltage relationships, the voltage-
dependence of the a2 subunit is more strongly influenced
by extracellular potassium and sodium [56, 57]. Since the
a2 isoform is localized to t-tubules, where extracellular
diffusion may be limited, it is possible that at high heart
rates where potassium may accumulate in extracellular
clefts, this may preferentially affect the activity of the a2
isoform. The steeper voltage-dependence (associated with
accumulation of potassium in the t-tubules) may therefore
preferentially enhance the activity of the a2 isoform during
the plateau of the action potential. The contribution of this
isoform to overall current is small (even in the t-tubule),
but it is possible that this preferential activation may affect
local sub-sarcolemmal sodium in the t-tubule microdomain
and have an impact on E–C coupling.
Pump regulation by intracellular signaling pathways
Adrenergic signaling pathways
The functional link between the adrenergic system and the
cardiac pump is well established, but remarkably, after
many decades of research, there is still disagreement about
the functional consequences of adrenoceptor activation on
pump activity. In general activation of PKA (via b1-
adrenoceptors linked to adenylate cyclase) and PKC (via
a1 adrenoceptors linked to phospholipase C) increases
stroke volume in ventricular muscle via phosphorylation of
L-type calcium channels, the ryanodine receptor and
phospholamban [58]. Pump inhibition is classically
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positively inotropic as it reduces calcium extrusion by
NCX and therefore increases calcium uptake to the SR.
Activation of both adrenoceptor pathways is likely, how-
ever, to also involve a concomitant increase in heart rate
and hence sodium influx. Thus, while Na pump activation
under such circumstances might be expected to limit the
positive inotropy (by limiting the rate-induced rise in
sodium) this effect may be minimal (in the face of the
profound increase in the calcium transient) and is probably
a price worth paying for maintaining calcium extrusion via
NCX and hence improving relaxation and diastolic func-
tion. Indeed, pump activation by the adrenergic system
appears to be essential to protect against sodium and cal-
cium-overload-induced arrhythmias (discussed in ‘‘The
functional role of phospholemman phosphorylation’’).
Protein kinase A
Most laboratories report activation of the pump by PKA
agonists in the heart [39, 59–68], some report inhibition
[69, 70], some no effect [71], while others report both
activation and inhibition depending on experimental design
[72]. The details of the molecular events underlying pump
regulation by PKA will be discussed below. The dis-
agreement in the functional effect of PKA on pump activity
is difficult to reconcile between different laboratories and
different techniques, but is perhaps best explained by the
relatively overlooked work of Gao et al. [72], who inves-
tigated pump activity using the whole cell patch clamp
technique in guinea-pig ventricular myocytes. They found
that the adrenoceptor agonist isoprenaline stimulates pump
activity in a PKA-dependent manner when intracellular
calcium is clamped to physiological or slightly supra-
physiological concentrations [68, 72], but isoprenaline
inhibits the pump in a PKA-dependent manner when
intracellular calcium is clamped to sub-physiological con-
centrations [70, 72]. In general laboratories reporting pump
inhibition by PKA buffer intracellular calcium below
100 nM (for example [69]), while those reporting pump
activation by PKA do not buffer calcium (for example [39,
61, 63])—which may account for the contradictory results
between different investigators. This effect of calcium
buffering on PKA-mediated pump activation is consistent
with our observation that the elevated sodium affinity of
the pump in PLM knockout myocytes is dependent on
pipette calcium, this effect being lost when calcium is
buffered below around 10 nM [73]. Indeed, calcium is also
reported to modify the effect of PKA activation on pump
activity in an identical fashion in tissues other than the
heart [74]. Whether this effect of calcium is a biophysical
quirk or a genuine physiological means to switch the pump
from a PKA-inhibitable to a PKA-activatable state is not
known. Calcium activation of Ca-sensitive enzymes such
as PKC may play a role, however in the intact heart, the
average intracellular calcium, which is dependent on heart
rate and adrenergic tone, will always normally exceed the
10–150 nM cut-off above which PKA stimulates the pump
[72, 75]. This would suggest that PKA inhibition of the
pump is of limited biological relevance in cardiac muscle,
but is perhaps important in cell types where intracellular
calcium is lower.
Protein kinase C
In some tissues there is convincing evidence that PKC
phosphorylation of the pump a subunit is a signal for pump
internalization and degradation (for example [76–78]), but
this does not appear to be the case in the heart. Again, there
is disagreement with respect to the functional effect of
PKC activation on the pump in the heart, with both acti-
vation [61, 79–81] and inhibition [82–84] reported. Again,
it has been suggested that intracellular calcium determines
the functional effect of PKC on the pump in the kidney
[74], and this may also prove to be the case in the heart.
However, an additional level of complication is the mul-
tiplicity of PKC isoform expression in the heart—with at
least PKCa, d and e found expressed [61], and therefore the
potential for PKC isoform-specific effects on pump activ-
ity. That calcium-sensitive PKCs activate the pump is
suggested by the observation that simply increasing
extracellular calcium is sufficient to increase pump Vmax,
presumably through an effect on these PKCs [85].
Nitric oxide
There is near-universal agreement that nitric oxide (NO)
stimulates the cardiac Na pump [86–89], although it is
reported to inhibit the pump in other tissues, notably the
kidney [90, 91]. NO synthesis in cardiac muscle may be
activated by natriuretic peptide receptors [86] and b3
adrenoceptors [89], and has also been reported to be con-
trolled by heart rate [92, 93], although the impact of the
latter on pump activity remains uninvestigated to date. It is,
however, noteworthy that all tissues in which NO is
reported to stimulate the pump either express PLM, or the
associated FXYD accessory protein is unknown. This rai-
ses the possibility that PLM is required for the stimulatory
effects of NO on the pump [94].
Phospholemman the kinase target
Phospholemman (PLM) was first identified as an abundant
phosphoprotein in the cardiac sarcolemma in 1985 [95],
and it was quickly recognized to be the principal sarco-
lemmal substrate for both PKA and PKC in the heart [95,
96]. Thereafter, it was proposed to form an anion
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conductance in its own right [97, 98], but remained
something of an orphan. Indeed, 13 years after its discov-
ery, its role in the heart remained something of a mystery:
As a major target for hormone-stimulated phosphorylation
in the heart, the physiological function of phospholemman
is likely to be an important one [99]: it was clearly
important, but just what did it do? The identification of the
FXYD family of pump regulators [11] of which PLM is a
member gave us our answer: PLM associates with the Na
pump in the heart [16, 59, 100–102], and modifies its
transport properties (see below).
PLM (FXYD1) is unique in the FXYD family in pos-
sessing phosphorylation sites in its carboxyl terminus that
are conserved across all vertebrate sequences cloned to
date (Fig. 1). PLM is phosphorylated at S63, S68, and
S/T69 by PKC, and at S68 by PKA [61, 103]. PLM S63 has
also been reported to be a substrate for NIMA kinase [104],
although there is no known functional connection between
this kinase and the pump.
There is not universal agreement over the exact func-
tional effect of PLM on the cardiac Na pump. In part, this
stems from the variety of experimental models and
approaches. These range from biochemists requiring a
precise kinetic analysis of what each part of the PLM
molecule does to the pump (for example [105]), to physi-
ologists who are perhaps more concerned to find out what
happens to the pump when the cell is exposed to agonist X,
Y, or Z (for example [39]). As will be discussed, not all
observations from different laboratories can be reconciled,
but a consensus on the functional role of PLM has emerged
in recent years.
Unphosphorylated PLM inhibits the cardiac Na pump.
The exact nature of the inhibitory effect has been reported
to be via a reduction in sodium affinity with no alteration in
maximum transport rate (in voltage-clamped and fluores-
cent sodium indicator SBFI-loaded ventricular myocytes
[39, 59, 81, 106] or following reconstitution of recombi-
nant ab with recombinant PLM [105]), a suppression of
pump-maximum transport rate (in voltage-clamped ven-
tricular myocytes [61–63, 107]), or a subunit isoform-
specific effects on both [108] (see below). There are also
reports that recombinant PLM activates the pump upon
reconstitution [109, 110], which will also be considered
below (‘‘Oxidant modification as a reversible regulator of
the pump’’).
The interaction between PLM and the a subunit of the
pump has been visualized as co-immunoprecipitation [16,
101], intermolecular crosslinking [101], and intermolecular
FRET [102]. Early studies on the relationship between
these proteins noted that they remained associated whether
or not PLM was phosphorylated, but that phosphorylation
appeared to alter their relative alignment such that the a
subunit was crosslinked less efficiently to phosphorylated
PLM [101]. These observations were confirmed and refined
by experiments that demonstrated that PLM-YFP and a1-
CFP exhibited significant (20 %) FRET, and that this
FRET was almost abolished when PLM was phosphory-
lated [102]. Hence, the PLM carboxyl terminus (where the
YFP fluorophore was fused) is in close proximity (\9 nm)
to the pump a subunit, and this distance is significantly
increased when PLM is phosphorylated.
Phospholemman and PKA
The kinase signaling pathways discussed in ‘‘Adrenergic
signaling pathways’’ that lead to Na pump activation are
now widely acknowledged to terminate at PLM. Phos-
phorylation of PLM increases pump activity by relieving
the inhibitory effect of PLM on the pump [39, 59], and in
some models actually increases Vmax of the pump [62, 81,
101]. The most convincing experiments in this regard come
from the PLM knockout mouse, which has a relatively
moderate cardiac phenotype (mild left ventricular hyper-
trophy and depressed in vivo cardiac function) consistent
with elevated pump activity unloading the SR via an effect
on NCX [111]. In myocytes isolated from PLM KO ani-
mals and their WT littermates, the sodium affinity of the
pump (assessed by simultaneous measurement of intracel-
lular sodium and pump current) is higher in the KO,
because the inhibitory effect of unphosphorylated PLM is
lost. Stimulation of PKA via b-adrenoceptor activation is
without effect in the KO, but increases pump activity in the
wild-type by increasing the sodium affinity—such that the
pump activity in wild-type myocytes stimulated with iso-
prenaline resembles that in the KO [39]. Hence, it was
proposed that the relationship between PLM and the pump
is analogous to the relationship between the SR calcium
ATPase SERCA and its regulatory protein phospholamban
(PLB) [39]: unphosphorylated accessory protein inhibits
the ATPase by reducing its affinity for the transported
cation, and this inhibition is relieved by phosphorylation.
Although there is strong homology between PLM and PLB
around the phosphorylation sites, they are evolutionarily
unrelated proteins, with opposite transmembrane orienta-
tions. Nevertheless, they bind and regulate two closely
related ion pumps in SERCA and the Na pump.
Human SRRCRCKFNQQQRTGEPDEEEGTFRSSIRRLSTRRR 
Chimp SRRCRCKFNQQQRTGEPDEEEGTFRSSIRRLSTRRR 
Mouse SKRCRCKFNQQQRTGEPDEEEGTFRSSIRRLSSRRR 
Rat SKRCRCKFNQQQRTGEPDEEEGTFRSSIRRLSTRRR 
Dog SRRCRCKFNQQQRTGEPDEEEGTFRSSIRRLSTRRR 
Xenopus Tropicalis SRKCRCKFNQHQRTGEPLEEEGTLRASIRRMSSRRL
Xenopus Laevis SRKCRCKFNQHQRTGEPLEEEGTLRASIRRLSSRRL
Fig. 1 Sequence alignment of phospholemman from different spe-
cies. The phosphorylation sites and palmitoylation/glutathionylation
sites plus surrounding residues are conserved across vertebrate classes
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Subsequent research has suggested that the relationship
between PLM and the Na pump is possibly more complex
than that between PLB and SERCA. PLB is a substrate for
PKA (and S16) and Cam kinase (at T17), with essentially
identical effects on SERCA activity of phosphorylation at
either site [112]. The analogous residues in PLM are S68
and S/T69, but PLM may also be phosphorylated at S63 by
PKC (discussed below). Several investigators have repor-
ted effects of phosphorylated PLM on Na pump maximum
transport rate in ventricular myocytes [61–63, 107]: PLB
has never been observed to alter the Vmax of SERCA.
Basal phosphorylation of phospholemman
One complication in the investigations into the relationship
between PLM and the Na pump is the relatively high basal
phosphorylation of PLM in ventricular muscle. In rat
ventricular myocytes, *30 % of PLM is phosphorylated at
S68 and *50 % is phosphorylated at S63 (such that
*40 % of PLM is phosphorylated at neither residue, and
*30 % is phosphorylated at both) [61]. This basal phos-
phorylation is the result of PKC activity, and underlying it
is a rapid turnover of phosphorylation and dephosphoryl-
ation: when PKC isoforms are acutely inhibited, PLM is
dephosphorylated at both sites with a half-life of 2–3 min
[61]. The consequences of this high basal phosphorylation
are twofold. Firstly, agonist-induced phosphorylation of
PLM in rat ventricular muscle generally elicits only a two-
to threefold increase in phosphorylation of S63 or S68,
(although the third PKC site S/T69 is essentially unphos-
phorylated in the basal state and its phosphorylation is
therefore very significantly elevated by PKC agonists [61]).
While this has not been formally investigated in other
species, PKA and PKC activation in mouse ventricular
myocytes also elicits only up to twofold increases in
phosphorylation of PLM S63, and up to fivefold increases
in phosphorylation of PLM S68 [81]. Secondly, the com-
parison of pump activities between PLM wild-type and KO
myocytes compares a mixture of phosphorylated and
unphosphorylated PLM in the wild-type, to the absence of
PLM in the KO. Since one of the factors likely to influence
PLM phosphorylation is the adrenergic state of the heart
when myocytes are prepared, ‘‘resting’’ PLM phosphory-
lation is likely to vary from laboratory to laboratory, and
even from day to day in the same laboratory. In addition,
and clearly related, is the observation that basal phos-
phorylation is extremely sensitive to the resting cellular
calcium load and hence is directly related to the ‘‘quality’’
of the isolated myocytes. This basal PLM phosphorylation
can be substantially reduced either by lowering extracel-
lular calcium or by treating cells with bisindolylmaleimide
implicating the calcium-activated PKCs in this basal tone
[61]. Consistent with this, we observe lower basal
phosphorylation when PLM is expressed in cultured cells,
or when cultured myocytes have been allowed to recover
from the stresses of isolation. These cells are accordingly
more responsive in terms of fold changes in phosphoryla-
tion following agonist application (for example see [15,
61]).
The relative contributions of basally phosphorylated and
unphosphorylated PLM to pump regulation in wild-type
myocytes was addressed by Pavlovic et al. [62]. A peptide
corresponding to the final 19 amino acids of rat PLM
(including all phosphorylation sites) was applied to the
intracellular face of myocytes from PLM wild-type and KO
animals using the whole cell configuration of the patch
clamp. This peptide reconstituted with and inhibited the
pump in both wild-type and KO myocytes—revealing the
functional contribution of basally phosphorylated PLM to
pump activity. When peptide phosphorylated by PKA at
S68 was applied, pump activity was stimulated in wild-type
cells (revealing the functional contribution of unphos-
phorylated PLM), but also surprisingly in KO cells. Hence,
while confirming the concept that unphosphorylated PLM
is an endogenous inhibitor of the pump, this investigation
raised the possibility that phosphorylated PLM actively
stimulates the pump rather than simply relieving an inhi-
bition. The ability to activate the pump must therefore lie
within the PLM phosphorylation sites. Reconstitution
experiments and functional evaluation of PLM/FXYD4
chimeras indicate that some inhibitory effect on the pump
(through a reduction in sodium affinity) is mediated by the
PLM transmembrane domain [105]. Therefore two regions
of PLM inhibit the pump: the transmembrane domain and
the intracellular region [62]. Whether wild-type, endoge-
nous PLM activates the pump in cardiac muscle to the
same extent as a peptide applied to KO cells through the
patch pipette is doubtful. Not only will full-length PLM
transmembrane domain exert an inhibitory effect on pump
sodium affinity, but phosphorylation has also recently been
found to promote palmitoylation of PLM, which itself
inhibits the pump (discussed below) [15].
Phospholemman and PKC: isoform-specific regulation?
Na pump activation by PKC in the heart also requires PLM
[81]. In mouse ventricular myocytes, phosphorylation of
PLM by PKC substantially increases pump Vmax [81], with
no change in sodium affinity in some reports [81], and an
increase in others [59]. The effects of PKA and PKC
activation turn out to be additive, both in terms of phos-
phorylation of PLM and functional effect on the pump. So
activating PKA after PKC elicits additional phosphoryla-
tion of PLM at S68, and increases pump sodium affinity
(against a background of already-increased Vmax), and
activating PKC after PKA causes further phosphorylation
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of S68 and increases pump Vmax [81]. Taken together, these
studies suggest that in murine ventricular myocytes, PKA
and PKC have access to different pools of PLM, and the
functional effect of phosphorylating these pools is differ-
ent. While this may reflect a pump isoform-specific effect
of PLM phosphorylation on the pump, in the mouse, almost
90 % of pump is a1-containing [19]. Hence, although there
is functional evidence to support the notion that PKA is
functionally linked to a1-containing pumps only [19, 113],
it is unlikely that the exclusive linking of PKC to an a2-
containing pool that is only *10 % of total myocyte pump
could account for the 60 % increase in pump Vmax
observed when PKC is activated in the mouse ventricular
myocytes [81].
That PKA and PKC are functionally linked to different
isoforms of the catalytic subunit of the pump in cardiac
muscle was first proposed even before the role of PLM in
regulating the pump had been discovered [114]. In the
Xenopus oocyte expression system, PKA phosphorylation
of PLM at S68 increases the sodium affinity of both a1 and
a2-containing pumps, whereas PKC phosphorylation of
PLM increases the turnover rate only of a2 containing
pump (to a level above the activity of pump expressed
without PLM) [108], closely paralleling the results
described above in mouse [81]. The functional effect of
both PKA and PKC activation on both pump isoforms in
this oocyte system requires phosphorylation of PLM S68
[108]. Importantly, the fact that this result was obtained in
a simple oocyte expression system would seem to rule out
any role for differential kinase targeting of PKA to an a1-
only pool and PKC to an a2-only pool of pump that might
account for observations made in mouse ventricular myo-
cytes [81]. Instead, this implies that while both a1 and a2-
containing pumps have an identical capability to sense
phosphorylation of PLM S68 (leading to a change in
sodium affinity), a2-containing pumps are uniquely able to
sense, additionally, phosphorylation at PLM S63 (and in all
likelihood PLM S/T69, which was not described at the time
the study was conducted). The impact of this additional
phosphorylation event is to increase the turnover rate of a2-
containing pumps above that observed in the absence of
PLM. The molecular basis of this insensitivity of the a1
subunit to phosphorylation of PLM S63 remains to be
determined: beyond the transmembrane domain [105], the
sites of interaction between PLM and pump a subunits
have not been defined. Given that the increase in a2 Vmax
induced by PKC phosphorylation is abolished by mutation
of PLM S68 [108], it is likely to be an electrostatic effect of
multiple phosphorylations in the PLM C terminus, rather
than a specific effect of PLM S63 phosphorylation per se.
Such a notion is supported by the fact that phosphorylation-
induced changes in FRET between PLM-YFP and CFP-a1
and PLM-YFP and CFP-a2 are indistinguishable [59]. That
said, the phosphorylation-induced reduction in FRET
between PLM-YFP and a2-CFP is perhaps incompatible
with the concept of an a2 subunit-specific activation (rather
than disinhibition) of the pump by S63 phosphorylated
PLM.
It is perhaps significant that there are notable sequence
differences between a1 and a2 subunits in a region of the N
domain that may be capable of interacting with PLM,
which might explain the isoform-specific effects of PLM
phosphorylation. Figure 2 models the regions of diver-
gence between a1 and a2 subunits in mammals on the
crystal structure of the porcine pump. Blue indicates little
or no divergence, yellow conservative changes, orange
moderate changes, and red major changes in sequence
between the isoforms. No Na pump crystal structure has yet
resolved a significant portion of the intracellular region of
the associated FXYD protein, which implies significant
mobility for this region. The flexible linker between PLM
helix 3 (H3) and helix 4 (H4 contains the phosphorylation
sites) may allow H4 to adopt multiple positions relative to
the a subunit depending on its phosphorylation state: in
other words, the PLM NMR structure may not accurately
represent the structure it adopts when complexed with the
pump. This is emphasized by the lack of sequence differ-
ence between a1 and a2 around the position that PLM H4
is modeled based on its NMR structure (Fig. 2b, save for
Q819 in a1 to A in a2), which is not concordant with the
specific activation of a2 by PKC phosphorylation of PLM.
However, regions of the N domain that are orientated
towards PLM in the E2 crystal structure do show diver-
gence between a1 and a2: in particular T407R, A409P,
L412T, and Q521I in a surface groove of the N domain
facing PLM (Fig. 2b). The presence of a positively charged
arginine in position 407 of a2, and removal of the nearby
hydrophobic leucine (in position 412 of a1), may be of
particular significance for transducing the effect of multiple
phosphorylations of PLM to the a2-containing pump if the
H3/H4 linker in PLM is able to flex sufficiently to allow H4
to interact with the a2 N domain in either E2 or the as yet
uncrystallized E1 state. Since the rate-limiting step in the
reaction cycle of the pump is the E2 to E1 transition [115],
the effect of PLM phosphorylation on a2 pump Vmax must
reflect an increase in the rate of this partial reaction.
Doubtless the mechanism underlying this will become
clearer when more structural information is available.
The elegant transgenic model in which the ouabain
affinities of Na pump a1 and a2 subunits are swapped
(SWAP mice [18]) has allowed the relative contributions of
PKA and PKC-mediated phosphorylation of PLM to reg-
ulation of a1- and a2-containing pumps in cardiac
myocytes to be assessed. The ouabain sensitivity of mouse
a1-containing pump is elevated by the mutations R111Q
and D122N in the first extracellular loop: Q111 and N122
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are found in the high affinity human and sheep a1 isoforms
and confer sensitivity to cardiac glycosides [116, 117]. The
ouabain sensitivity of a2-containing pumps is reduced by
mutations L111R and N122D in the same position. Hence
the ouabain sensitivities of the cardiac pumps are swapped
without altering isoform distribution or enzymatic activity
[18]. In the wild-type mouse, the dominant a1 isoform is
ouabain-resistant, and a2 is ouabain-sensitive, such that
10–20 lM ouabain will block essentially all a2-containing
pumps, while leaving *90 % of the a1-containing pumps
active. The same low ouabain concentration specifically
blocks a1-containing pumps only in SWAP mice, meaning
the relative contributions and regulation of a1 and a2 can
be determined in SWAP and wild-type mice, respectively
[59]. Much as was reported in oocytes [108], phosphory-
lation of PLM by PKA increases the sodium affinity of
both a1 and a2 isoforms. Phosphorylation of PLM by PKC
also elevates sodium affinity of both isoforms, but again
only elevates the Vmax of a2-containing pumps [59]. For
now, the basis of the a2-specific effect of PLM remains
unresolved. Apart from the sequence differences discussed
above, it may be relevant that there are clear biochemical
differences between a1b1 and a2b1 pumps in terms of
thermal stability and interaction with phospholipids [118]
that could account for this.
Phospholemman and phosphatases
Relatively little research has been conducted to date on the
pathways leading to PLM dephosphorylation. Shortly after
the cloning of PLM, adenosine receptor agonists were
reported to attenuate adrenoceptor agonist-induced phos-
phorylation of PLM independent of cellular cAMP [119].
Subsequent work found that PLM is a substrate for both
PP1 and PP2A, and it therefore provides a functional link
between both these phosphatases and the Na pump [120].
More recently it has been shown that PLM S68 (and pos-
sibly T69) are substrates for PP1, while S63 is probably a
PP2A substrate [121]. Moreover, phosphorylation of S68 is
regulated by the PP1 inhibitor inhibitor-1: intracellular
application of an inhibitor-1-derived peptide, or overex-
pression of inhibitor-1 leads to enhanced phosphorylation
of PLM S68 and increased Na pump currents [121]. In
failing human hearts, PP1 hyperactivity may contribute to
impaired b-adrenoceptor responsiveness [122], and this
reduced phosphorylation of PLM at S68 [121]. Under-
phosphorylation of PLM in failing cardiac tissue leading to
reduced Na pump activity may be a causal event in the
well-characterized elevation of intracellular sodium in
human heart failure [123, 124]. Hence, the PLM dephos-
phorylation pathways may be a ripe therapeutic target in
the management of elevated intracellular sodium in the
failing heart.
The functional role of phospholemman phosphorylation
In the context of adrenoceptor activation increasing myo-
cardial contractility, it is pertinent to ask why hearts need
PLM. On the face of it, enhanced Na pump activity, by
increasing the driving force for calcium efflux through
NCX, will tend to oppose the positive inotropy achieved
through activation of L-type calcium channels, SERCA,
and the ryanodine receptor by PKA. Genetic deletion of
PLM slightly reduces cardiac contractility in vivo, although
this is partly offset by a (possibly adaptive) reduction in
pump subunit expression [111]. It turns out that the small
price paid in terms of reduced inotropy when phosphory-
lated PLM activates the pump is more than balanced by the
protective effect of PLM phosphorylation [125]. In myo-
cytes from PLM KO animals, an increase in stimulation
frequency plus b-adrenoceptor activation with isoprenaline
causes a larger rise in intracellular sodium, greater SR
T407R 
A409P 
L412T 
Q819A 
N domain 
A domain 
N domain 
A B
Fig. 2 Sequence divergence between a1 and a2 subunits as a basis of
differential regulation by PLM? Na pump a1 and a2 sequences from
the species indicated were aligned with Clustal (for full alignment,
see Supplement 1). A heat map was generated using the porcine
crystal structure (3B8E.pdb [3]) to indicate positions of surface
conservation and divergence between a subunits using a 1–5 scale
(annotated on the Clustal alignment). The b1 subunit is shown in
magenta, and PLM (phosphorylated at S63, S68, and T69) is shown in
green, positioned according to [15]. Color coding of the a subunit is
as follows: (1) Dark Blue 85? % conserved (where both a1 and a2
are the same, allowing only one outlier in both groups). (2) Light blue
either no consensus for a1 and a2, or used if a1 and a2 cannot be
discriminated significantly. (3) Yellow conservative change, repre-
sented by ‘;’ in the Clustal alignment. Also used even if there is a
single outlier in one group. (4) Orange moderate change, represented
by ‘.’ in the Clustal alignment. (5) Red major change. Also used even
if a single outlier is present. If multiple outliers are present, this is
downgraded to yellow. a Surface divergence between a1 and a2 is
particularly notable in the N domain. b Major changes between a1
and a2 that may be influenced by phosphorylation of PLM are
highlighted
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calcium content, and bigger calcium transients than in
myocytes from wild-type animals from essentially identical
baselines in unstimulated cells [125]. However, the over-
loading of the SR with calcium leads to more spontaneous
calcium transients and hence arrhythmias in PLM KO
myocytes. Therefore PLM phosphorylation is a protective
event in the heart. By limiting sodium (and therefore cal-
cium overload), PLM protects the heart from arrhythmias
and contractile disturbances linked to adrenoceptor acti-
vation. There is a clear parallel to the human condition
catecholamine-induced polymorphic ventricular tachycar-
dia (CPVT), but to date, no human mutations of PLM
associated with CPVT have been described. The clinical
significance of the PLM/Na pump relationship may be
confined to the under-phosphorylation of PLM described in
‘‘Phospholemman and phosphatases’’.
Phospholemman palmitoylation: the new kid on the block
S-palmitoylation is the reversible covalent post-transla-
tional attachment of the fatty acid palmitic acid to the thiol
group of cysteine, via an acyl-thioester linkage [126]. In
recent years, protein S-palmitoylation has emerged as an
important and common post-translational modification in a
variety of tissues [127]. Protein S-palmitoylation is cata-
lyzed by palmitoyl acyltransferases, reversed by protein
thioesterases, and occurs dynamically and reversibly
throughout the secretory pathway in a manner analogous to
protein phosphorylation [126]. Many different classes of
protein have been identified as targets for palmitoylation,
including G-proteins [128, 129], ion channels [130],
transporters [131], receptors [132], and protein kinases
[133, 134]. Of particular relevance to this review, palmi-
toylation can control ion channel/transporter activity,
stability, or subcellular localization [127, 135]: it has the
potential to induce substantial changes in the secondary
structure and therefore function of intracellular loops
through their recruitment to the inner surface of the
membrane bilayer.
PLM is palmitoylated at two intracellular cysteines, C40
and C42, just beyond the transmembrane domain [15].
Notably, these cysteines are conserved across species, but
also one or both cysteines are found in analogous positions
throughout the FXYD family: FXYD2, 5 and 7 have one,
and FXYD3, 4 and 6 have two [136], and all are predicted
to be palmitoylated [15], meaning FXYD protein palmi-
toylation may be a universal means to regulate the pump.
Unpalmitoylatable mutant PLM is degraded with a shorter
half life than wild-type PLM in transiently transfected
cells, but the principal functional effect of PLM palmi-
toylation is inhibition of the Na pump [15]. The inhibitory
effect of PLM on the pump is abolished following appli-
cation of the pharmacological inhibitor of palmitoyl
acyltransferases 2-bromopalmitate. Indeed, given the rela-
tively modest effect of this inhibitor on PLM
palmitoylation, it is possible that palmitoylation switches
PLM from a pump activator to an inhibitor.
Although the palmitoyl acyltransferase that palmitoy-
lates PLM is yet to be identified, one important regulator of
PLM palmitoylation is its phosphorylation status. Para-
doxically, phosphorylation of PLM at S68 by PKA
increases PLM palmitoylation [15]. Hence, one post-
translational modification of PLM that activates the Na
pump promotes a second that inhibits it. The molecular
basis of phosphorylation promoting palmitoylation can
probably be explained by reference to the NMR structures
of unphosphorylated and S68 phosphorylated PLM [137,
138] (Fig. 3). S68 phosphorylation of PLM increases the
mobility of PLM helix 4 relative to unphosphorylated
PLM, without inducing major changes in the overall
structure of the protein. This probably increases the
accessibility of the cysteines in PLM helix 3 to the pal-
mitoyl acyltransferase enzyme(s) that palmitoylate PLM.
As for the physiological and functional significance of
enhanced PLM palmitoylation following PKA activation,
this remains to be seen. Site-specific reagents to distinguish
which cysteine in PLM is palmitoylated following S68
phosphorylation of PLM do not exist (nor do they for other
palmitoylation sites in other proteins). Molecular models of
the PLM/Na pump complex (Fig. 4) suggest PLM C42
could mediate the inhibitory effect of PLM palmitoylation
on the pump, as the side chain of this amino acid is ori-
entated towards the pump a subunit, and C40 is orientated
away. Palmitoylation of C42 (with incorporation of the
palmitate into the lipid bilayer) may pull PLM H3 across
the intracellular mouth of a sodium-binding site in the a
subunit in order to inhibit the pump. Conversely, palmi-
toylation of C40 on the opposite side of H3 would oppose
such a movement by pulling H3 in the opposite direction.
This raises the possibility that while the overall effect of
PLM palmitoylation on the pump is inhibitory, the indi-
vidual palmitoylation sites may have opposing effects on
pump activity through their reorientating effects on PLM
H3 (Fig. 4).
Other roles of phospholemman
Although beyond the scope of this review, it is important to
note that several other functional roles are ascribed to PLM
in the heart. Phosphorylation of PLM at S68 is associated
with inhibition of NCX [139, 140]. It is proposed that NCX
inhibition is necessary in the context of Na pump activation
by PLM to prevent the enhanced sodium gradient driving
NCX to unload the SR of calcium following adrenergic
stimulation [140]. In addition, PLM modulates L-type
calcium channel gating when expressed with Cav1.2 in
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heterologous cells: it slows activation and deactivation, and
increases the rate of voltage-dependent inactivation [141]
via an effect of the extracellular FXYD motif [142]. It
remains to be determined if endogenous PLM associates
with and regulates L-type calcium channels in the heart: it
is possible these effects simply reflect the abnormal inter-
action of an over-expressed membrane-spanning protein
with a sarcolemmal ion channel.
Although the original proposal [98] that PLM oligo-
merizes to form an ion channel and is involved in
regulation of cell volume is not now widely favored,
convincing experimental evidence suggests that PLM does
oligomerize [102, 143], at least following expression in
heterologous cells. PLM-YFP and PLM-CFP exhibit sig-
nificant FRET with each other, which is increased
following PLM phosphorylation [102], or by phosphomi-
metic mutations of PLM [143]. Peptides corresponding to
the transmembrane domain of PLM form stable homo-
tetramers [144, 145] and progressive acceptor photoble-
aching experiments also suggest that the PLM–PLM
oligomer is composed of three or more molecules [59]. The
physiological significance of this in cardiac muscle remains
to be determined. The analogy to PLB and SERCA may be
relevant: PLB monomers inhibit SERCA [146], while PLB
C40-palm 
C42-palm 
C40,C42-palm 
S68-phos, 
C40-palm 
S68-phos 
S63,S68,T69-phos 
C42-glut 
Fig. 3 The many faces of
phospholemman. The NMR
structure of PLM (2JO1.pdb
[137, 138]) is in the center, and
the post-translational
modifications of PLM discussed
in the text are shown. The
functional effect of each
modification on pump activity
(compared to unmodified PLM)
is indicated by green (for
activation), red (for inhibition),
or both red and green where this
remains to be determined
H2 
H4 
H2 
H3 
H4 
H3 
Fig. 4 Position of the palmitoylation sites of phospholemman relative
to the a subunit. PLM is shown in green, a subunit transmembrane
region in blue, N domain in cyan, P domain in yellow, and A domain in
purple. The b subunit is red. Sodium (purple spheres) is shown in its
proposed binding sites (reviewed in [6]). Helices H2, H3, and H4 of
PLM are labeled. C42 of PLM is orientated towards the a subunit, and
C40 away, meaning palmitoylation of C42 may pull PLM H3 across
the intracellular mouth of a sodium-binding site in the a subunit.
Conversely, palmitoylation of C40 would oppose such a movement by
pulling H3 in the opposite direction
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pentamers are thought to be inactive [147]. PLM may also
exist in multiple states in cardiac muscle: in a 1:1 complex
with the pump [59], and in homo-oligomers—possibly a
storage pool. If some Na pump in the heart is PLM-free
(which has been suggested [62]) the storage pool would
represent a means to increase the ‘responsiveness’ of the
pump to adrenergic stimulation, by as-yet unidentified
means.
Oxidant modification as a reversible regulator
of the pump
In contrast to the apparent contradictions in the literature
regarding the effect of PKA and PKC agonists on the
cardiac pump, the exquisite sensitivity of Na pump activity
in the heart to oxidant stress is widely accepted. Shattock
and Matsuura [38] investigated the direct effect of free-
radical induced stress on the pump in voltage-clamped
rabbit ventricular myocytes. Their work indicated that
pump current was reduced by approximately 50 % at all
membrane potentials after a 10-min exposure to photoac-
tivated rose-bengal (a singlet oxygen and superoxide
generator). Subsequent work found pump activity was
significantly reduced by intracellular application of thiol-
modifying reagents, or depletion of cellular glutathione
[148], confirming a functional link between pump activity
and protein sulfhydryl status.
Oxidant modification and regulation of the pump has
also been the subject of more recent investigation. Glu-
tathionylation is the reversible conjugation of the
tripeptide glutathione to protein cysteines in a mixed
disulfide. Many classes of protein have been found to be
regulated by glutathionylation, including metabolic
enzymes such as glyceraldehyde-3-phosphate dehydroge-
nase [149], kinases including PKA [150] and PKC [151],
G proteins such as H-Ras [152] and ion transporters and
pumps such as the ryanodine receptor [153] and SERCA
[154]. Like phosphorylation and palmitoylation, glutath-
ionylation allows dynamic, reversible post-translational
regulation of all manner of signaling and metabolic
pathways [155]. Glutathionylation is no longer considered
solely to be a consequence of oxidative stress, and occurs
under physiological conditions in the absence of overt
oxidative burden [156]. Unlike phosphorylation and
palmitoylation, glutathionylation is generally non-enzy-
matic, and occurs by direct reaction between oxidized/
modified protein sulfhydryls and cellular glutathione,
direct reaction between protein sulfhydryls and modified
(e.g., nitrosylated) glutathione, disulfide exchange between
protein sulfhydryls and glutathionylated proteins, or direct
reaction between protein sulfhydryls and glutathione in the
presence of oxidants [155]. The lack of enzymes to cata-
lyze glutathionylation does not result in a lack of
specificity for this modification, as the vast majority of
cysteine sulfhydryls are not susceptible to glutathionyla-
tion because their pKa is above 8.0, such that they remain
protonated and hence non-reactive at physiological pH.
Redox sensitive cysteines that are susceptible to glutath-
ionylation may be deprotonated to the thiolate anion at
physiological pH as a result of a favorable local envi-
ronment for that particular cysteine, usually achieved by
the presence of positively charged amino acids nearby to
receive the proton. Glutathionylation is reversed enzy-
matically by glutaredoxins, thioredoxins and sulfiredoxin,
and can be removed non-enzymatically by disulphide
exchange with glutathione [155].
The a subunit of the cardiac Na pump has recently been
reported to be glutathionylated to regulate its activity
[157]. Exposure of purified Na pump to oxidized gluta-
thione causes glutathionylation of conserved cysteines in
the a subunit actuator and nucleotide binding domains.
Glutathionylation of the cardiac pump occurs in the basal
state, and is promoted during cardiac hypoxia, causing
profound pump inhibition. Interestingly, ATP binding and
a subunit glutathionylation are competitive: glutathiony-
lation only occurs at ATP concentrations below 0.5 mM,
and ATP is modeled to be unable to bind to the glutath-
ionylated a subunit [157], which accounts for the inhibitory
effect of glutathionylation on the pump. Pump a2 subunit is
more sensitive to inhibition by glutathionylation than
a1, which may be relevant in the light of the different
physiological roles for these subunits discussed in ‘‘Intro-
duction’’ and ‘‘Pump regulation by the prevailing cellular
environment’’. It is proposed that rapid, reversible pump
inhibition by glutathionylation during depletion of cellular
ATP (for example during cardiac ischemia or hypoxia) is a
means to protect the pump a subunit against irreversible
oxidation, and protect the cell against ATP depletion by the
pump [157]. This protection of the pump and energy
expenditure, however, comes at a price—the inhibition of
the pump and the associated elevation of intracellular
sodium that is known to occur rapidly after the onset of
ischemia [158–160].
The Na pump in the heart is also reported to be regulated
by glutathionylation of its b rather than a subunit [161].
The cardiac b1 subunit is found glutathionylated in
unstimulated myocytes, and exogenous oxidants such as
peroxynitrite or hydrogen peroxide promote additional
glutathionylation of the b1 subunit when applied to intact
cardiac myocytes [161]. A similar result is observed fol-
lowing activation of NADPH oxidase, which is reported to
colocalize with the cardiac pump and mediate angiotensin
II-induced pump inhibition via a PKCe dependent pathway
[84]. The functional effect of b1 subunit glutathionylation
is to destabilize the interaction between cardiac a and b
subunits, and decrease the Vmax of the pump through a
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reduction of the rate constant for the E2 to E1 transition in
the reaction cycle [161]. The cysteine residue within the b1
subunit that becomes glutathionylated is in position 46,
which is perhaps surprising given this amino acid is well
within the membrane spanning domain of the b1 subunit in
the crystal structure of the pump in the E2 state [4]. Recent
work has shed light on this however: when the E1 state of
the pump is stabilized, C46 of b1 becomes both more
susceptible to glutathionylation in the presence of oxidants,
indicating the molecular rearrangement during transition
from E2 to E1 is sufficient to expose this site to the cytosol
[162]. Ouabain, by stabilizing the pump in the E2 confor-
mation, reduces the susceptibility of the b1 subunit to
glutathionylation [162].
A similar signaling mechanism has been proposed to
mediate inhibition of the cardiac pump by PKA [69]. In
rabbit cardiomyocytes, PKA stimulation with the adenylyl
cyclase activator forskolin is reported to activate NAPDH
oxidase in a PKCe-dependent manner, which leads to
glutathionylation of the cardiac b1 subunit and pump
inhibition. Herein a remarkable contradiction emerges in
the regulation of the Na pump by PKA and PKC in the
heart. The majority of researchers report PLM-dependent
activation of the pump by both kinases [39, 59, 61–63, 81,
101, 108, 121, 125], but some describe PLM-independent,
NADPH oxidase-dependent inhibition of the pump by the
same kinases over essentially identical timescales [69, 84,
161]. Unless the effect of calcium buffering discussed
above (‘‘Protein kinase A’’) can really account for these
differences, it is certainly difficult to reconcile such con-
tradictory observations. It is also difficult to conceive how
it might be useful for the heart to have the same pathways
mediating such contradictory effects on pump activity in
the same cell type. A key determinant may be the presence
of PLM, since this has been reported to relieve the inhi-
bition of the pump caused by glutathionylation of its b1
subunit [110] (discussed in ‘‘Phospholemman: integrating
multiple post-translational modifications?’’ below). This
may render PLM-containing pumps resistant to oxidative
inhibition, and at the same time activatable by protein
kinases. Doubtless such incongruities will be the topic of
future research and debate.
A signaling pathway through the b3-adrenoceptor is also
linked to regulation of the cardiac pump. Activation of b3
receptors leads to pump stimulation in an NO and guany-
late cyclase-dependent manner, through a reduction in the
glutathionylation of the pump b1 subunit [89]. Hence,
cellular mechanisms exist to enhance de-glutathionylation
as well as glutathionylation. The molecular basis by which
NO might reduce b1 subunit glutathionylation remains
unclear. It may be relevant that neither a nor b subunits of
the pump are likely targets of cGMP signaling pathways,
whereas PLM is [163].
Phospholemman: integrating multiple post-translational
modifications?
Experiments in which recombinant FXYD proteins are
reconstituted with the Na pump have recently suggested
that recombinant PLM is capable of activating the pump
[109, 110], although some investigators report the opposite
phenomenon in very similar model systems (for example,
see [105]). A component of this activation could be
explained by the stabilizing effect of PLM on the pump
complex [118, 164], however other mechanisms have also
been invoked. PLM is proposed to be glutathionylated to
relieve oxidant-induced inhibition of the pump following
glutathionylation of its b1 subunit [110]. PLM glutath-
ionylation is promoted by the same signaling pathways that
promote b1 subunit glutathionylation, but remarkably PLM
glutathionylation is suggested to be downstream of b1
subunit glutathionylation. That is, rather than being glu-
tathionylated as an alternative to b1 subunit C46, the
presence of PLM facilitates de-glutathionylation of C46 of
b1, with concomitant glutathionylation of PLM [110].
PLM and the b1 subunit of the pump are a considerable
distance apart in the current crystal structures in the E2
state [3, 4]. Glutathionylation occurs at PLM C42, and
requires the adjacent amino acid K43, presumably to pro-
vide a locally positively charged environment for the
deprotonation of C42. Thus the presence of PLM activates
the pump in the sense that it is protected from oxidant-
induced inhibition as a result of the reduced glutathiony-
lation of C46.
Again, the paradigm of PLM as a pump activator during
redox signaling in cardiac muscle does not sit well with the
consensus regarding the role of PLM in phosphoregulation
of the pump. Multiple studies using numerous model sys-
tems agree that dephosphorylated PLM inhibits the pump
(discussed above). Nor can redox and phosphoregulation
by PLM be easily separated since it is now well established
that oxidizing species activate PKA and PKG in ventricular
muscle [165–167]. Indeed, hydrogen peroxide treatment of
ventricular myocytes, which has been reported to inhibit
the pump via b1 subunit glutathionylation [161], leads to
substantial phosphorylation of PLM at S68 because it
activates type 1 PKA (by promoting an inter-protein
disulfide bond between its two regulatory subunits) [165].
Since phosphorylation of PLM at S68 promotes its palm-
itoylation [15], it is difficult to exactly predict the
consequences for the pump. Palmitoylation and glutath-
ionylation may compete for the same cysteine; the ability
of this cysteine to receive either glutathione or palmitate
will depend on whether it is already modified with the
other. Hence, PLM may be a pump activator (through
glutathionylation) or inhibitor (through palmitoylation)
depending on the state of cysteine 42, which is determined
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by the phosphorylation status of PLM, adrenergic state of
the tissue, and redox state of the cell. Figure 3 depicts some
of the post-translational modifications of PLM discussed,
and Fig. 5 summarizes our current knowledge of these
pathways and how they may interact.
Future directions
To date, remarkably few studies have investigated the
effects of endogenous agonists of adrenoceptors on Na
pump activity in ventricular muscle. Although a consider-
able amount of evidence points to the involvement of
pathways linked to b1, b3 and a1 adrenoceptors, the
additional activation of b2 adrenoceptors by adrenalin/
noradrenalin must also be considered, as this generates a
cAMP signal localized to the sarcolemma by caveolae (in
which the Na pump resides, discussed below) [168, 169].
The consequences of the simultaneous activation of all the
signaling pathways discussed above are hard to predict, and
the balance between them will undoubtedly vary between
health and disease. The multiprotein complexes that direct
the different signaling events themselves remain largely
unidentified. In addition, the use of endogenous agonists
brings into play the endogenous uptake mechanisms for
these agonists: the metabolism of adrenalin and noradren-
alin taken up via uptake 2 in ventricular myocytes is
through oxidative deamination by mitochondrial mono-
amine oxidase A, which generates hydrogen peroxide
[170]. The oxidative burden imposed by this hydrogen
peroxide (which will activate several of the pathways dis-
cussed above) can be significant enough to contribute to
cardiac failure [170] and cell death during cardiac ischemia
[171], and therefore warrants investigation in the context of
the regulation of the cardiac Na pump by the adrenergic
system.
Direct regulation of the pump by small molecules
Regulation by lipids
While perhaps not the subject of recent research, it is
noteworthy that the cardiac Na pump is regulated by lipid
species. Palmitoyl carnitine and lysophosphatidylcholine
are potent pump inhibitors [172, 173], while long-chain
fatty acyl CoA derivatives [174] and monoacylglycerols
[175] stimulate the pump over concentration ranges it is
likely to encounter in myocytes. These activators increase
the pump’s ATP affinity, and it is suggested that they
maintain Na pump activity against a backdrop of falling
ATP during cardiac ischemia [174]. Sodium overload as a
result of pump inhibition is a central feature of cardiac
ischemia. In the ischemic heart, the pump is inhibited by
the accumulation of a cytosolic substance whose pro-
duction is inhibited by anti-oxidants [176], which is likely
to be an oxidized lipid, but whose instability has pre-
cluded identification. The molecular identity of this
inhibitor has recently been proposed to be oxidized glu-
tathione [157].
While the stimulatory effect of long-chain acyl CoA on
the pump is thought to be due to specific binding of the
acyl-CoA to an intracellular domain of the pump, rather
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than non-specific effects on the bilayer [174], the mecha-
nism by which lipids alter pump activity in the heart has
not been rigorously investigated. It is now clear that the
phospholipid environment in which the pump resides is one
determinant of its activity. The cardiac pump is located in
caveolae (discussed in ‘‘Caveolae and caveolins’’ below),
which are rich in sphingolipids and cholesterol. In general,
phospholipid interactions [177] and in particular choles-
terol [178] are important to stabilize the pump, and PLM in
particular of the FXYD family stabilizes the interaction
between phosphatidylserine and the pump a subunit [164].
The functional relevance of this to the cardiac enzyme is
unclear, since phosphatidylserine is without effect on pump
activity [178]. That said, the stabilizing effect of PLM may
be physiologically relevant: pump expression is reduced in
the PLM KO heart [111, 179] and it has been suggested this
may be due to the loss of the stabilizing effect of PLM
making the pump more susceptible to degradation [118,
164]. It is proposed that phosphatidylserine stabilizes the
pump through an interaction close to a subunit ninth
transmembrane domain, which is where the FXYD protein
also interacts [164]. PLM palmitoylation may therefore
modify the relationship between the a subunit and phos-
phatidylserine, since the palmitate moieties present when
PLM is palmitoylated at C40 and C42 must also be
accommodated in the lipid bilayer. On the other hand
although palmitoylation controls the turnover rate of PLM,
it appears to do so independently of an effect on the deg-
radation rate of the a subunit [15].
Endogenous cardiotonic steroids
Although the cardiotonic effects of Na pump inhibitors
such as digoxin and ouabain have been established for
centuries, consensus on the finer molecular details of this
phenomenon has been hard to reach. That the cardiotonic
steroid binding site in the pump a subunit is physiologi-
cally important is demonstrated by its conservation across
all vertebrates [180], although the sensitivity of the pump
to ouabain does vary from species to species, with the rat
and mouse particularly insensitive. The existence of
endogenous ligands for this site was first proposed in the
1970s (reviewed in [180]), and anti-digoxin antibodies
were successfully used to purify Na pump inhibitors from
plasma in 1980 [181]. It is therefore perhaps remarkable
that the chemical identity of this compound or group of
compounds remains elusive [182]. Variously it has been
identified as endogenous ouabain [183, 184], marinobuf-
agenin [185], digoxin [186] and telocinobufagin [187]. Its
physiological effect on blood pressure and heart rate is
revealed by the use of the commercial anti-digoxin anti-
body Digibind, which reduces blood pressure and heart rate
when administered to the brain [188], and reduces blood
pressure when administered to many different models of
hypertension (reviewed in [182]).
Positive inotropy following pump inhibition by cardio-
tonic steroids is as a result of reduced NCX activity
increasing the calcium content of the SR. The pump iso-
form responsible for this phenomenon in the heart has been
the subject of some debate. In rat ventricular myocytes,
selective inhibition of a2-containing pumps (11 % of total
pump) increases contractility without a global increase in
intracellular sodium through the sodium-loading of a sub-
sarcolemmal compartment functionally linked to NCX
[24]. Through this functional coupling to NCX (co-ordi-
nated by the linker protein ankyrin-B: see below), it has
been proposed that the pump a2 subunit is a fundamental
regulator of calcium handling and therefore contractility in
the heart [189]. Experiments in transgenic animals in which
the ouabain affinity of the a2 subunit has been reduced also
clearly indicate that ouabain-induced inotropy requires
inhibition of the a2-containing pumps [22, 190]. However
when the ouabain sensitivity of the a1-containing pumps is
enhanced by mutagenesis, these too are able to facilitate
ouabain-induced increases in cardiac contractility in an
NCX dependent manner [18]. Hence both isoforms of the
pump mediate positive inotropy. The role of endogenous
cardiotonic steroids in controlling cardiac inotropy is
probably somewhat limited however, since baseline and
b-adrenoceptor agonist-stimulated in vivo cardiac con-
tractility is essentially identical between wild-type and all
strains of ouabain affinity-modified mice [18, 190]. In
animals with enhanced sensitivity of a1-containing pumps
to ouabain, the hypertrophic response to pressure overload
induced by aortic banding is elevated, implicating cardio-
tonic steroids in this pathological remodeling, but not in
normal physiological cardiac function [191].
Regulation by other associated proteins
Caveolae and caveolins
Precise control of the subcellular location of the Na pump
is essential for co-ordinated control of its activity. In car-
diac muscle essentially all active pump is found in
caveolae [192]. Caveolae are small flask-like invaginations
of the cell membrane around 50–100 nm in diameter,
found in almost all cells of the body. They represent a
specialized form of lipid raft, an area of the cell membrane
enriched in cholesterol and sphingolipids, characterized by
the presence of the protein caveolin. The lipid environ-
ment, caveolin content and morphology of caveolae are
central to their diverse functional roles, which include co-
ordination of signal transduction, cholesterol homeostasis,
and endocytosis. One of caveolae’s best-characterized roles
The cardiac Na pump 1371
123
is as a signalosome, a compartment that brings together
components of signal transduction cascades (including
receptors, effectors and targets) [193]. Within caveolae, the
20-residue scaffolding domain of caveolin (caveolin 3 in
cardiac muscle) interacts with a complementary caveolin-
binding domain in proteins, which enables oligomeric
caveolin to act as a regulatory scaffold for macromolecular
signaling complex formation [194]. Caveolae have been
assigned a key role in regulation of signaling in the heart.
For example, a1- and b2-adrenoceptors are found exclu-
sively in caveolae-containing membrane fractions of the
adult heart [195, 196], while b1-adrenoceptors are in both
caveolae and the bulk sarcolemma [197]. Cardiac caveolae
are also sites of enrichment of G proteins, including Gas,
Gi, and Gq [195, 198] (although see [196]). Effectors of
adrenoceptors (including adenylyl cyclase V/VI, protein
kinase A (RII), GRK2, phospholipase Cb, PP2A and
eNOS) are likewise concentrated in the cardiac caveolar
domain [196–199], as are their downstream targets (for
example, PLM). The distribution of receptors, effectors and
their targets is key to the efficiency and fidelity of their
coupling [168, 169, 196].
Apart from the Na pump, a considerable number of
cardiac ion transporters are resident in cardiac caveolae:
voltage-gated sodium channels [200], L-type calcium
channels [199], voltage gated potassium channels [201],
ATP-sensitive potassium channels [202], NCX1 [203]
(although this has been challenged [204]), and the plasma
membrane calcium ATPase (PMCA) [205]. Physical co-
localization of ion transporters in the caveolar compart-
ment may functionally link ion flow by providing a
restricted diffusional space [206] and facilitates hormonal
regulation of these transporters by placing them physically
adjacent to signaling molecules. For example, regulation of
a sub-population of L-type calcium channels by b2-
adrenoceptors requires their colocalization in caveolae
[199]. Furthermore, the presence of ion transporters in
caveolae is likely to have functional relevance beyond
signal transduction since the lipid composition of the
bilayer in which an ion transporter resides is likely to
influence its activity. Membrane cholesterol modulates
many aspects of ion channel function: activity of the Na
pump, for example, is regulated [207] and stabilized (dis-
cussed above [178]) by the cholesterol content of the
membranes within which it resides.
The presence of the cardiac pump in caveolae is
achieved through the presence of a caveolin binding motif
[208]: either uXXXXuXXu at the N terminus, or
uXuXXXXu at the C terminus, where u represents an
aromatic amino acid [209]. These motifs are highly con-
served between isoforms and species. Although only
*30 % of cardiac a subunit is found in caveolin-enriched
microdomains purified by sucrose gradient centrifugation
from ventricular myocytes [210], essentially 100 % of the
b subunit is in these microdomains [192]. Given the well-
established requirement for the b subunit to form a func-
tional pump, it is likely that non-caveolar a subunit
represents pools from both biosynthetic and degradation
pathways: the majority of pump activity (*75 %) is
caveolar [192].
The relative functional concentration of pump isoforms
in cardiac t-tubules [19, 24] must be reconciled with the
finding that the majority of cardiac ab is localized to
buoyant caveolin-enriched membranes [192]. Whether
caveolae are found in cardiomyocyte t-tubules has been the
subject of some debate. Mature skeletal muscle t-tubules
are reported to be largely free of caveolin 3 by some
researchers [211], but not others [212]. However immu-
nofluorescent (for example [199, 213]) and electron
microscopy [214, 215] studies clearly indicate that both
caveolin 3 and intact caveolae are found in the t-tubule
system of ventricular muscle, albeit only in regions outside
the dyad. Functionally, localization of the pump to cardiac
caveolae is likely to be important to achieve colocalization
with the signaling complexes that regulate it: PKA [196,
197], PKC isoforms (which migrate into caveolae upon
activation [216]) and NADPH oxidase [84]. The local
protein composition of pump-containing caveolae, which
remains largely un-investigated, is clearly important both
for acute pump regulation as well as in establishing local
ion gradients and sub-sarcolemmal pools of sodium.
Ankyrin-B
In addition to the well-characterized interaction between
the cardiac Na pump and NCX1 [18, 189, 190], the pump is
a member of a much larger multi-protein complex in car-
diomyocyte t-tubules, which also includes the SR IP3-
receptor, and is co-ordinated by the cytoskeletal linker
protein ankyrin-B [217]. It has long been known that
ankyrin-B binds the Na pump [218] at a conserved ALLK
motif in the large third intracellular loop that contains the
active site [219]. The role of this interaction is well
understood for the localization of the pump to the baso-
lateral membrane in polarized epithelia [220, 221], and its
importance in cardiac muscle is now emerging. An anky-
rin-B loss-of-function mutation (E1425G) is the basis of
type 4 long QT syndrome as a result of disrupted co-
ordination of the pump/NCX/IP3-receptor complex leading
to calcium mishandling and arrhythmias [222]. The phys-
ical colocalization, and therefore functional coupling of
these proteins is severely impaired in animals heterozygous
for ankyrin-B knockout [217]. Therefore a second macro-
molecular complex exists in cardiac t-tubules, distinct from
the classic ryanodine receptor/L-type calcium channel
dyad. This complex is unique to cardiac muscle (ankyrin-B
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expression being *10-fold lower in skeletal muscle [217]),
and appears to be an adaption to optimize calcium handling
by recruiting and functionally coupling the Na pump and
NCX1 in cardiomyocyte t-tubules.
Cardiac sodium pump as a therapeutic target
in cardiovascular disease
A reduction of the transarcolemmal Na gradient in cardiac
myocytes has been implicated in a variety of pathologies
including ischemia/reperfusion [223, 224], hypertrophy
and heart failure (HF) [123, 124, 225–227]. While a
component of the elevation of Na in hypertrophy and HF
may reflect an increase in sodium influx [52], there is a
large body of evidence showing that Na pump function
may also be compromised in cardiac hypertrophy [225–
227] and failure [228].
In hypertrophy and HF many aspects of E–C coupling are
clearly altered, however, the elevation in intracellular
sodium may contribute to (1) the negative force-frequency
relationship, (2) slowed relaxation (3) arrhythmias, and (4)
impaired mitochondrial energetics [123, 229, 230]. In an
elegant series of studies, O’Rourke and colleagues have
recently shown that mitochondrial calcium plays a key role
in linking ATP production to ATP demand (i.e., mechanical
activity) [229–232]. Mitochondria take up calcium via a
uniporter, and extrude it using a Na/Ca exchanger. Fast
calcium transients in cardiac mitochondria match those in the
myocyte cytosol [233]: as calcium rises in the cell, so does
mitochondrial calcium and this activates Krebs Cycle
dehydrogenases to increase NAD reduction to NADH, and
therefore step-up ATP production [232]. This relationship,
which crucially matches ATP supply to demand, is blocked
when cytosolic sodium is elevated [233]: the rise in sodium
activates Na/Ca exchange in the inner mitochondrial mem-
brane and this keeps mitochondrial calcium low preventing
ATP supply meeting demand—leaving the heart metaboli-
cally compromised. In myocytes from failing hearts in which
cytosolic sodium is elevated, blockade of mitochondrial Na/
Ca exchange is sufficient to restore mitochondrial function
by enhancing mitochondrial calcium accumulation [229].
Not only might elevated cytosolic sodium contribute to the
known metabolic insufficiency in hypertrophied hearts but
Kohlhaas et al. [232] have shown that this increases mito-
chondrial free radical formation in failing hearts further
exacerbating injury. Moreover, acute cardiac glycoside
toxicity (assessed by increased intracellular sodium, reduced
mitochondrial calcium and increased reactive oxygen spe-
cies production in isolated myocytes) is ameliorated by
inhibition of the mitochondrial Na/Ca exchanger with CGP-
37157, while in vivo the positive inotropic effect of ouabain
is actually enhanced by CGP-37157 [231].
This raises the interesting paradigm that strategies that
increase myocyte sodium efflux, and therefore restore the
sodium gradient, may be an effective means to restore
mitochondrial ‘supply–demand’ matching in hypertrophy
and failure. The positive effect on the Na pump of agents
used in the treatment of cardiac hypertrophy and failure has
been noted by others: ACE inhibitors, angiotensin receptor
blockers, aldosterone antagonists, NO-donors and insulin
are all known to stimulate the Na pump and, in clinical
trials, these agents have all been shown to be protective
[234]. Clearly this is in direct contradiction to the historic
use of cardiotonic steroids as inotropes, and remains
untested either in animal models or in the clinic. Digitalis,
however, appears to provide symptomatic relief rather than
a positive effect on long-term prognosis. In the largest trial
of its kind, the Digitalis Investigation Group showed
digoxin reduced hospitalization due to worsening HF
symptoms but had no long-term effect on mortality [235].
Whether the functional benefit of pump stimulators to treat
hypertrophy and failure (in terms of restoration of mito-
chondrial demand coupling) will outweigh the functional
impediment (likely as a result of increased NCX activity
unloading the SR) remains to be seen. Indeed, the ideal
pharmacology would seem to be a combination of a1-pump
activation and a2-pump inhibition to calcium-load the SR
via NCX without imposing a significant sodium load [24,
189, 190]. Time will tell whether we can take advantage of
our hard-won knowledge of the cardiac pump to achieve
such a clinical application.
Concluding remarks
In conclusion, all manner of regulatory pathways converge
on the cardiac Na pump, and it sits exquisitely poised to
respond to the changing demands of the cardiovascular
system. To some extent a number of these regulatory
pathways seem to cancel each other out, while others
complement each other, and this raises questions such as
‘why is it essential to fine-tune intracellular sodium so
precisely?’ and ‘which regulatory pathways are the most
important?’. It is undoubtedly not necessary to fine-tune
intracellular sodium to the nearest micromolar, but it is
perhaps not precision but accuracy that is important for the
cardiac Na pump. That is, the set-point for intracellular
sodium and Na pump activity may not need to be precisely
clamped, but rather need to vary depending on prevailing
physiological conditions (heart rate, sympathetic drive and
so on). As for which are the most important regulatory
pathways, the simplest answer may be that it depends on
the state of the heart when it receives a particular signal
whether that signal leads to Na pump activation or inhi-
bition. Hence one can conceive of adrenoceptor activation
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leading to kinase-induced pump activation via PLM in the
absence of redox stress, and oxidant-induced pump inhi-
bition in a heart with reduced anti-oxidant reserve. That
said, the most compelling information is perhaps that PLM
knockout myocytes are more prone to calcium-overload
induced arrhythmias when treated with a b adrenoceptor
agonist [125]. This unequivocally highlights the protective
role of PLM as a pump activator following adrenergic
stimulation in the heart—although it does not address the
relative contributions of pump activation via PLM phos-
phorylation versus pump disinhibition via b1 subunit
deglutathionylation, which must perhaps wait for new
transgenic models to be developed.
Another crucial factor in understanding the control of
the cardiac pump is to appreciate the importance of local
signaling networks and local ion gradients. This is not
simply distinguishing t-tubular from surface sarcolemmal
pumps, or a1 from a2 pumps, but drilling down into
identifying subpopulations of pumps, the ion transporters
with which they co-localize, the regulatory mechanisms
that control them, their physiological significance, and
measuring the sodium concentration ‘seen’ by each sub-
population. In other words our existing experimental tools
must be improved so that we do not simply rely on whole
cell pump currents and fluorescence measurements as
indices of activity and substrate availability. Cardiac
myocytes are complicated beasts: we are already accu-
mulating evidence for local ion gradients and functional
coupling of some but not all pumps to other sarcolemmal
ion transporters. To continue to investigate global rather
than local pump control is to ignore the reductionist
approach that has served so well in the first 50 years of
investigating this remarkable, ubiquitous enzyme complex.
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